|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000040040 |
|
最近更新日期: Date of Last Refreshed on: |
2020-11-19 00:04:45 |
|
注册时间: Date of Registration: |
2020-11-19 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
电针针刺提高心脏骤停后综合征良好神经功能生存率的随机对照试验性研究 |
|
Public title: |
Effect of Electroacupuncture on survival with a favorable neurological outcome of Post-cardiac Arrest Syndrome: a pilot randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
电针针刺提高心脏骤停后综合征良好神经功能生存率的随机对照试验性研究 |
|
Scientific title: |
Effect of Electroacupuncture on survival with a favorable neurological outcome of Post-cardiac Arrest Syndrome: a pilot randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
曾瑞峰 |
研究负责人: |
曾瑞峰 |
|
Applicant: |
Zeng Ruifeng |
Study leader: |
Zeng Ruifeng |
|
申请注册联系人电话: Applicant telephone: |
13760872664 |
研究负责人电话:
Study leader's |
13760872664 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
raynorz@gzucm.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
raynorz@gzucm.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市大德路111号 |
研究负责人通讯地址: |
广东省广州市大德路111号 |
|
Applicant address: |
111 Dade Road, Guangzhou, Guangdong, China |
Study leader's address: |
111 Dade Road, Guangzhou, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广东省中医院 |
||
|
Applicant's institution: |
Guangdong Provincial Hospital of Chinese Medicine |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
广东省中医院伦理委员会ZF2020-051-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广东省中医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-10-30 00:00:00 | ||
|
伦理委员会联系人: |
李晓彦 |
||
|
Contact Name of the ethic committee: |
Li Xiaoyan |
||
|
伦理委员会联系地址: |
广州市越秀区大德路111号研修楼1912 |
||
|
Contact Address of the ethic committee: |
Room 1912, Training building, 111 Dade Road, Guangzhou, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
020-81887233-35943 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
llbgs@gzucm.edu.cn |
|
研究实施负责(组长)单位: |
广东省中医院急诊科 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Emergency Medicine of Guangdong Provincial Hospital of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市大德路111号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
111 Dade Road, Guangzhou, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
广州市科技创新委员会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Guangzhou Science and Technology Department |
||||||||||||||||||||||
|
研究疾病: |
心脏骤停 |
||||||||||||||||||||||
|
Target disease: |
Cardiac Arrest |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
观察电针百会、足三里穴对于心脏骤停后综合征的神经功能恢复的疗效和安全性 |
||||||||||||||||||||||
|
Objectives of Study: |
To observe the efficacy and safety of electroacupuncture at Baihui(GV20) and Zusanli(ST36) on the survival with a favorable neurological outcome of Post-cardiac Arrest Syndrome |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①心脏骤停因为呼吸衰竭或低血容量性休克导致;②院内心脏骤停者;③年龄为18-85周岁;④心脏骤停患者经抢救后恢复自主循环≥20分钟;⑤恢复自主循环后、使用镇静治疗前(如有),格拉斯哥昏迷评分≤8;⑥法定代理人签署知情同意书者;⑦进行高级生命支持者。 |
||||||||||||||||||||||
|
Inclusion criteria |
① Cardiac arrest is caused by respiratory failure or hypovolemic shock; ② In-Hospital Cardiac Arrest; ③ Aged 18-85 years old; ④ Patients with return of spontaneous circulation (ROSC) that is sustained for ≥20 minutes; ⑤ Glasgow coma score ≤8 after ROSC, and before sedation (if any) ; ⑥The legal representative signed the informed consent; ⑦advanced life support is conducted. |
||||||||||||||||||||||
|
排除标准: |
①无灌注时间>10分钟(从心脏骤停到开始胸外按压的时间);②低灌注时间>60分钟(从开始胸外按压到恢复自主循环的时间);③严重的血流动力学不稳定(定义为以去甲肾上腺素以>1μg/Kg/min的流速泵入仍存在休克血压);④肿瘤晚期及其他疾病终末状态导致的心脏骤停;⑤属于不可逆原因(如严重创伤、中毒)引起的心脏骤停患者;⑥心源性心脏骤停(急性梗死、恶性心律失常、心力衰竭等);⑦穴位定位处有皮损、伤口、皮肤病等影响针刺者;⑧过敏体质者,或已知对治疗方式过敏,如金属过敏者;⑨孕妇或哺乳期妇女。 |
||||||||||||||||||||||
|
Exclusion criteria: |
① No-flow time >10 min (time from collapse to initiation of external cardiac massage); ② Low-flow time >60 min (time from initiation of external cardiac massage to ROSC); ③ Major hemodynamic instability (defined as a continuous epinephrine or norepinephrine infusion at a flow rate >1 μg/Kg/min); ④Cardiac arrest caused by advanced tumor and other end-of-state diseases; ⑤Cardiac arrest caused by an irreversible cause (such as Severe trauma and poisoning); ⑥ Cardiogenic cardiac arrest (acute infarction, malignant arrhythmia, heart failure, etc.); ⑦ Acupoint with lesions, wounds, or skin diseases affects acupuncture; ⑧Allergic persons, or known to be allergic to treatment, such as metal. ⑨ pregnant or lactating women. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-11-01 00:00:00至 To 2021-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-12-01 00:00:00 至 To 2021-08-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
合格受试者被随机分配到试验组组或对照组(1:1比例)。随机化采用SPSS 17.0进行,区块随机化规模为4人,等比分配。分配后将按顺序编号存放在密封的信封中,直至分配干预。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Eligible patients enrolled in the interventional part are being randomly assigned to either the EA group or the control group (1:1 ratio). The randomization is carried out by SPSS 17.0 with a block randomization size of four. To guarantee rigorous methodology, the allocation will be sequentially numbered stored |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
由于本研究涉及针刺,难以做到双盲。但为了尽量避免过程中的偏倚,拟采用以下具体措施:①研究者严格按照随机的原则入组受试者;②参与结局评价的医生为非研究人员,使试验疗效评价处于盲态;③血液检测及数据分析及统计者为非临床研究人员。 |
|
Blinding: |
Since this study involves acupuncture, it is difficult to achieve double blindness. However, in order to avoid the bias in this process, the following specific measures are proposed: ①Researchers are recruited in strict accordance with the principle of randomization; ②The physicians participating in the outcome evaluation are non-researchers, making the trial efficacy evaluation blind; ③The laboratory technicians and the biostatisticians will be blinded to the assigned treatments. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2022.6 网络公开; ResMan |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2022.6 network publicity |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |